Augmenix Inc.
Augmenix wins CE Mark for TraceIT marking agents
Augmenix said it won CE Mark approval in Europe for its TraceIT fiducial marker and TraceIT gel system radiology marking agents.
Proteus Digital closes $172M round for ingestible sensor tech | Medtech funding for the week of July 28, 2014
Augmenix raises $11M for surgical hydrogels as Varian’s purchase option expires
Massachusetts-based Augmenix is hoping it can make it to the U.S. market with the $10.8 million funding round it just closed, the company said this month.
Funding roundup: PneumRx nets $33 million
Here’s a roundup of the latest dealflow and investment news:
Augmenix touts first commercial application of prostate treatment
Augmenix Inc. announced the first commercial implantation of its SpaceOAR prostate-rectum separation hydrogel system in Europe.
Doctors at Germany’s Aachen University Hospital implanted the CE Mark-approved absorbable spacer system, designed to protect tissue underneath the prostate during radiation therapy, according to the company.